IL310031A - A combination of cellular therapy and an immune modulatory compound - Google Patents

A combination of cellular therapy and an immune modulatory compound

Info

Publication number
IL310031A
IL310031A IL310031A IL31003124A IL310031A IL 310031 A IL310031 A IL 310031A IL 310031 A IL310031 A IL 310031A IL 31003124 A IL31003124 A IL 31003124A IL 310031 A IL310031 A IL 310031A
Authority
IL
Israel
Prior art keywords
combination
cell therapy
immunomodulatory compound
immunomodulatory
compound
Prior art date
Application number
IL310031A
Other languages
English (en)
Hebrew (he)
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of IL310031A publication Critical patent/IL310031A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
IL310031A 2017-05-01 2018-05-01 A combination of cellular therapy and an immune modulatory compound IL310031A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762492947P 2017-05-01 2017-05-01
US201762538670P 2017-07-29 2017-07-29
US201762549390P 2017-08-23 2017-08-23
US201762580433P 2017-11-01 2017-11-01
US201762596753P 2017-12-08 2017-12-08
PCT/US2018/030545 WO2018204427A1 (en) 2017-05-01 2018-05-01 Combination of a cell therapy and an immunomodulatory compound

Publications (1)

Publication Number Publication Date
IL310031A true IL310031A (en) 2024-03-01

Family

ID=62563245

Family Applications (2)

Application Number Title Priority Date Filing Date
IL310031A IL310031A (en) 2017-05-01 2018-05-01 A combination of cellular therapy and an immune modulatory compound
IL270250A IL270250B2 (en) 2017-05-01 2018-05-01 Combination of a cell therapy and an immunomodulatory compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL270250A IL270250B2 (en) 2017-05-01 2018-05-01 Combination of a cell therapy and an immunomodulatory compound

Country Status (19)

Country Link
US (1) US20200078404A1 (cg-RX-API-DMAC7.html)
EP (2) EP3618842B1 (cg-RX-API-DMAC7.html)
JP (2) JP7299841B2 (cg-RX-API-DMAC7.html)
KR (2) KR102707505B1 (cg-RX-API-DMAC7.html)
CN (2) CN118948892A (cg-RX-API-DMAC7.html)
AU (2) AU2018263887B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019022893A2 (cg-RX-API-DMAC7.html)
CA (1) CA3061945A1 (cg-RX-API-DMAC7.html)
DK (1) DK3618842T3 (cg-RX-API-DMAC7.html)
ES (1) ES2967467T3 (cg-RX-API-DMAC7.html)
FI (1) FI3618842T3 (cg-RX-API-DMAC7.html)
IL (2) IL310031A (cg-RX-API-DMAC7.html)
MA (1) MA51871A (cg-RX-API-DMAC7.html)
MX (1) MX2019012975A (cg-RX-API-DMAC7.html)
PH (1) PH12019502470A1 (cg-RX-API-DMAC7.html)
PL (1) PL3618842T3 (cg-RX-API-DMAC7.html)
PT (1) PT3618842T (cg-RX-API-DMAC7.html)
SG (1) SG11201910143TA (cg-RX-API-DMAC7.html)
WO (1) WO2018204427A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100221T1 (it) 2014-12-05 2021-07-12 Memorial Sloan Kettering Cancer Center Anticorpi bersaglianti l'antigene di maturazione delle cellule e metodi d'uso
CN110691792A (zh) 2017-01-10 2020-01-14 朱诺治疗学股份有限公司 细胞疗法的表观遗传学分析及相关方法
EP3582782B1 (en) 2017-02-17 2023-06-07 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
JP7308187B2 (ja) 2017-05-26 2023-07-13 アブビトロ リミテッド ライアビリティ カンパニー ハイスループットポリヌクレオチドライブラリーシーケンシングおよびトランスクリプトーム解析法
BR112020005077A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019090364A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
SG11202104188VA (en) * 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
EP3876958A1 (en) * 2018-11-08 2021-09-15 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
JP2022529720A (ja) * 2019-04-22 2022-06-23 スタートン セラピューティクス インコーポレイテッド レナリドミドまたは他の免疫調節剤の持続投与
EP3958875A4 (en) * 2019-04-25 2023-05-10 Purdue Research Foundation MANIPULATED NATURAL KILLER CELLS TARGETING PURINGERIC SIGNALING, THEIR CONSTRUCTS AND METHODS OF USE
AU2020355222A1 (en) * 2019-09-27 2022-03-24 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
US20220412954A1 (en) 2019-11-05 2022-12-29 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
MX2022005524A (es) * 2019-11-07 2022-08-25 Juno Therapeutics Inc Combinacion de una terapia de celulas t y (s)-3-[4-(4-morfolin-4-i lmetil-benciloxi)-1-oxo-1,3-dihidro-isoindol-2-il]-piperidino-2,6 -diona.
CN115087731A (zh) * 2019-12-06 2022-09-20 菲特治疗公司 用小化合物增强iPSC衍生的效应免疫细胞
WO2021148019A1 (zh) * 2020-01-22 2021-07-29 科济生物医药（上海）有限公司 病毒载体转导细胞的方法
KR20220152227A (ko) * 2020-02-12 2022-11-15 주노 쎄러퓨티크스 인코퍼레이티드 Ｂｃｍａ-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도
WO2021188770A1 (en) * 2020-03-18 2021-09-23 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
US20230178239A1 (en) 2020-05-13 2023-06-08 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
WO2022137181A1 (en) * 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
CN113173991B (zh) * 2020-12-31 2023-03-28 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
CA3227745A1 (en) * 2021-07-29 2023-02-02 Takeda Pharmaceutical Company Limited Car-expressing immune cells that specifically target mesothelin and uses thereof
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE68919715T2 (de) 1988-12-28 1995-04-06 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
JP4065567B2 (ja) 1996-07-24 2008-03-26 セルジーン コーポレイション 置換２―（２，６―ジオキソピペリジン―３―イル）フタルイミド類及び―１―オキソイソインドリン類ならびにＴＮＦαレベルの減少方法
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
EP1019439B1 (en) 1997-10-02 2011-11-16 Altor BioScience Corporation Soluble single-chain t-cell receptor proteins
TR200101500T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
IL139344A0 (en) 1998-05-19 2001-11-25 Avidex Ltd Soluble t cell receptor
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
NZ513953A (en) 1999-03-18 2001-09-28 Celgene Corp Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
WO2002068414A2 (en) 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
CA2457652C (en) 2001-08-31 2012-08-07 Avidex Limited Soluble t cell receptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1549748B1 (en) 2002-10-09 2014-10-01 Immunocore Ltd. Single chain recombinant t cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
US8747290B2 (en) 2007-12-07 2014-06-10 Miltenyi Biotec Gmbh Centrifuge for separating a sample into at least two components
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
DK2406284T5 (en) 2009-03-10 2017-06-12 Biogen Ma Inc ANTI-BCMA ANTIBODIES
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN107880101B (zh) 2011-11-11 2021-12-21 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ700362A (en) 2012-04-11 2016-09-30 Us Health Chimeric antigen receptors targeting b-cell maturation antigen
RU2018130123A (ru) 2012-05-03 2018-11-07 Фред Хатчинсон Кансэр Рисёч Сентер Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
IL237315B (en) 2012-08-20 2022-07-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
AU2014376328A1 (en) 2014-01-13 2016-07-21 Christine E. BROWN Chimeric antigen receptors (CARs) having mutations in the Fc spacer region and methods for their use
PL3888674T3 (pl) * 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
EP3193915A1 (en) * 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
KR102612313B1 (ko) * 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
WO2016046724A1 (en) 2014-09-22 2016-03-31 Sacmi Cooperativa Meccanici Imola Societa' Cooperativa Line for the production of individual products in succession in a continuous cycle
EP4310097A3 (en) 2014-12-05 2024-04-03 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SMT202100221T1 (it) 2014-12-05 2021-07-12 Memorial Sloan Kettering Cancer Center Anticorpi bersaglianti l'antigene di maturazione delle cellule e metodi d'uso
HUE056074T2 (hu) 2014-12-12 2022-01-28 2Seventy Bio Inc BCMA kiméra antigénreceptorok
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
US20180140602A1 (en) * 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
IL255697B2 (en) 2015-05-18 2023-11-01 Tcr2 Therapeutics Inc Compositions and methods for TCR programming using fusion proteins
US10001483B2 (en) * 2015-06-26 2018-06-19 Celgene Corporation Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017058754A1 (en) * 2015-09-28 2017-04-06 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
CU20180121A7 (es) 2016-04-01 2019-05-03 Kite Pharma Inc Receptores de antígenos quiméricos y células t
MX2019004181A (es) * 2016-10-13 2019-10-30 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que implican moduladores de la ruta metabólica de triptófano.
CA3041284A1 (en) * 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
MX2019005029A (es) * 2016-11-03 2019-10-24 Juno Therapeutics Inc Terapia de combinación de una terapia de células t y un inhibidor de tirosina cinasa de bruton (btk).
CA3040914A1 (en) * 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
KR20230156808A (ko) * 2016-12-03 2023-11-14 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포의 조절 방법
CA3045355A1 (en) * 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
CN110545826A (zh) * 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
CN109752300A (zh) 2019-01-02 2019-05-14 五邑大学 一种涂料生产安全智能巡检机器人、系统及方法

Also Published As

Publication number Publication date
BR112019022893A2 (pt) 2020-05-19
CN111182909A (zh) 2020-05-19
AU2025206408A1 (en) 2025-08-14
EP4327878A2 (en) 2024-02-28
KR20200026805A (ko) 2020-03-11
CA3061945A1 (en) 2018-11-08
CN118948892A (zh) 2024-11-15
IL270250B2 (en) 2024-06-01
MA51871A (fr) 2020-03-11
KR20240139092A (ko) 2024-09-20
PL3618842T3 (pl) 2024-02-19
JP7299841B2 (ja) 2023-06-28
AU2018263887B2 (en) 2025-04-24
AU2018263887A1 (en) 2019-11-21
DK3618842T3 (da) 2024-01-02
JP2020518591A (ja) 2020-06-25
EP3618842B1 (en) 2023-10-18
ES2967467T3 (es) 2024-04-30
WO2018204427A1 (en) 2018-11-08
EP3618842A1 (en) 2020-03-11
PH12019502470A1 (en) 2021-01-11
KR102707505B1 (ko) 2024-09-20
RU2019138707A (ru) 2021-06-02
EP4327878A3 (en) 2024-05-01
JP2023116720A (ja) 2023-08-22
MX2019012975A (es) 2020-08-03
RU2019138707A3 (cg-RX-API-DMAC7.html) 2021-12-21
IL270250B1 (en) 2024-02-01
IL270250A (cg-RX-API-DMAC7.html) 2019-12-31
US20200078404A1 (en) 2020-03-12
PT3618842T (pt) 2024-01-12
SG11201910143TA (en) 2019-11-28
FI3618842T3 (fi) 2023-12-15

Similar Documents

Publication Publication Date Title
IL310031A (en) A combination of cellular therapy and an immune modulatory compound
IL274361A (en) A combination of cellular therapy and a gamma secretase inhibitor
PT3582989T (pt) Estrutura de bateria e protetor
EP3547896A4 (en) EXTRANASAL STIMULATION DEVICES AND METHODS
IL250573A0 (en) Methods and devices related to electrical stimulation
EP3313506A4 (en) GASTROINTESTINAL STIMULATION DEVICES AND USES THEREOF
SG10202104163VA (en) Implantable encapsulation devices
GB201707153D0 (en) Therapy
GB201716838D0 (en) Airbag assembly including internal and external thethers
IL264451B1 (en) A combination of abt-199 and achmetalstat for the treatment of aml
GB201808541D0 (en) Testing of defibrillator electrodes
GB201719646D0 (en) Therapy
GB201708663D0 (en) Therapy
HUE070997T2 (hu) Másodlagos akkumulátor és ahhoz való egység
GB201618508D0 (en) Implantable device
IL270011B (en) Medicinal compounds and methods
IL267105A (en) implantable device
GB201709860D0 (en) Device and charger therefor
GB2586987B (en) Pacemaker Device
PL3006081T3 (pl) Zewnętrzny rozrusznik serca/kardiowerter
ZA201900091B (en) Implantable device
GB2559442B (en) Implantable device
HK40025054A (en) Combination of a cell therapy and an immunomodulatory compound
EP3487525A4 (en) COMBINATION THERAPY WITH CD19-ADC AND RCHP
GB201715430D0 (en) Therapy